Nordic Life Science cares about your privacy

Finnish NADMED, a University of Helsinki spin-out, has partnered with US specialty laboratory Doctor’s Data to make its NAD biomarker measurement available to healthcare practitioners across the United States.

AstraZeneca has signed a drug discovery collaboration and licensing agreement with the AI therapeutics company insitro. The deal, worth up to approximately USD 1.5 billion, aims to identify new drug targets and therapies for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.

Gothenburg-based OnDosis has entered a strategic collaboration with Adare Pharma Solutions, a US contract development and manufacturing organization (CDMO), to advance its lead ADHD program toward the US market. The partnership gives OnDosis commercial-scale manufacturing capacity in the US.

Aiforia has announced a commercial agreement with PathAI, a member of the Roche Group.

FluoGuide has entered a collaboration with medical technology company Leica Microsystems to advance precision surgery for brain tumors by combining its lead product, FG001, with Leica's surgical microscope systems.

Hansa Biopharma has signed a collaboration with Amsterdam-based Cradle. Hansa will use Cradle's AI-driven protein design and engineering platform across its research and development work to develop new immunomodulatory treatments for severe autoimmune diseases.

The company is investing USD 2 billion in Summit Therapeutics and launching a clinical collaboration that will combine Summit's PD-1/VEGF bispecific antibody ivonescimab with AstraZeneca's antibody drug conjugates (ADCs), starting in gastrointestinal cancers.